Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma

Table 3 Univariate and multivariate analysis

Factor		n (%)	Univariate		Multivariate
			HR (95%CI)	P value	HR (95%CI)	P value
Chemo status1	Neo-Adjuvant	37 (11)	-	-	-	-
	Adjuvant	290 (89)	0.95 (0.65-1.38)	0.7854	0.97 (0.67-1.43)	0.8961
Age1, yr	Mean ± SD	61.5 ± 14	1.02 (1.01-1.03)	0.0008	1.02 (1.01-1.03)	0.0006
Sex	Men	221 (68)	-	-
	Women	106 (32)	1.00 (0.77-1.31)	0.9859
Race/ethnicity	Non-hispanic white	118 (36)	-	-
	Black	33 (10)	1.48 (0.96-2.27)	0.0765
	Hispanic white	88 (27)	1.16 (0.84-1.59)	0.3576
	Asian/pacific islanders	88 (27)	1.00 (0.73-1.37)	1.0000
Tumor location	Proximal	98 (30)	-	-
	Distal	100 (31)	0.90 (0.65-1.24)	0.5173
	Whole	59 (18)	0.99 (0.69-1.43)	0.9621
	Middle	70 (21)	0.94 (0.67-1.33)	0.7395
Grade	Well differentiated	1 (0)	-	-
	Moderately differentiated	70 (21)	0.38 (0.05-2.73)	0.3338
	Poorly differentiated	234 (72)	0.48 (0.07-3.43)	0.4642
	Undifferentiated	18 (6)	0.57 (0.07-4.31)	0.5843
	Unknown	4 (1)	0.41 (0.04-4.55)	0.4687
Tumor size	≤ 5cm	117 (36)	-	-
	> 5cm	145 (44)	1.33 (1.02-1.75)	0.0379
	Unknown	65 (20)	0.98 (0.66-1.46)	0.9322
T stage	T2	24 (7)	-	-
	T3	163 (50)	2.18 (1.17-4.05)	0.0135
	T4a	96 (29)	2.90 (1.54-5.45)	0.0009
	T4b	44 (13)	4.86 (2.48-9.53)	< 0.0001
N stage	N0	38 (12)	-	-
	N1	261 (80)	1.47 (0.99-2.20)	0.0588
	N2	15 (5)	1.98 (0.95-4.11)	0.0666
	N3	13 (4)	1.90 (0.94-3.84)	0.0731
Node status	N-	38 (12)	-	-
	N+	289 (88)	1.51 (1.01-2.25)	0.0449
AJCC7 group1	II	187 (57)	-	-	-	-
	III	140 (43)	1.79 (1.39-2.30)	< 0.0001	1.81 (1.41-2.33)	< 0.0001

¹Included in multivariate model. AJCC: American joint commission on cancer; Chemo: Chemotherapy.